We have investigated twelve pyrimidinedione compounds with potent HIV activity and the ability to inhibit both virus entry and reverse transcription in an effort to determine a lead microbicide for product development. The candidate compounds were evaluated for efficacy against subtype B, C and E clinical virus strains in fresh human peripheral blood mononuclear cells and against CCR5-tropic virus strains in both monocytes-macrophages and dendritic cells.
Microbicide-specific biological assays and toxicity evaluations were also performed in a variety of established and fresh human cells as well as against Lactobacilli strains common to the vaginal environment. These evaluations resulted in the identification of congeners with cyclopropyl and cyclobutyl substituents at the N-1 of the pyrimidinedione as the most active molecules in the structure-activity relationship series. The pyrimidinediones represent excellent microbicide candidates in light of their significantly high efficacy against HIV-1 (sub-nanomolar concentration range), potency (TI > 1 million), solubility profiles, and dual mechanism of antiviral action which includes two early steps of virus replication prior to the integration of the virus considered most important for microbicidal activity A recent report issued by UNAIDS on the global AIDS epidemic sighted significant gains in the prevention of new HIV infections in a number of countries that are most affected by the AIDS epidemic [34] . Many of these countries have seen changes in sexual behavior followed by a decline in the number of new HIV infections. These behavioral changes include increasing condom use among young people with multiple partners and encouraging signs that young people are waiting longer to have sexual intercourse in some of the most heavily affected countries [34] . However, the report also states that despite these declines in new HIV infections, the AIDS epidemic is far from over and that the rates of new HIV infections continue to rise in many other countries. HIV/AIDS continues to be the leading cause of death in Africa [34] .
Despite intensive research, a vaccine to prevent HIV infection has not yet been successfully developed. In the absence of a prophylactic vaccine, antiretroviral therapy (ART) has been the primary mechanism utilized to prevent disease progression and prolong the survival of infected individuals. A wide variety of antiretroviral (ARV) agents are currently approved for use, targeting numerous steps in HIV replication such as attachment, fusion, reverse transcription, integration, and proteolytic processing. With the use of combination therapystrategies, resulting in the evolution of highly active antiretroviral therapies, or HAART, profound suppression of plasma viral load for prolonged periods of time have resulted in significant declines in AIDSrelated morbidity and mortality in developed countries where the therapies can be afforded [23, 29] . Although HAART regimens have improved the prognosis for HIV-infected individuals, challenges to effective use of these therapeutic strategies still remain, including issues of adherence, side effects and toxicities, drug resistance and persistent viral replication in latent reservoirs. These challenges necessitate the development of alternative strategies to combat the spread of HIV including prevention strategies in the form of vaginal and rectal topical microbicides. With the incidence of HIV infections in women on the rise, especially in underdeveloped countries [34] , the development and clinical evaluation of topical microbicides has achieved world-wide focus. It has been suggested that a microbicide with 60% efficacy introduced into 73 low-income countries, could prevent 2.5 million HIV infections over 3 years [36] . For these reasons, topical microbicides are an ideal HIV prevention strategy allowing a woman to take responsibility for her own protection from sexually transmitted disease [3, 33] especially in societies where women are unempowered. Minimally, a microbicide product should be safe, acceptable by the user, affordable, stable and effective without compromising existing physical barriers to STI transmission [33] . Microbicides are currently being developed in gel, cream, film, suppository, sponge and intravaginal ring formats, providing both a physical barrier which the virus needs to penetrate as well as specifically targeting critical steps of the virus replication cycle such as virus entry and reverse transcription [32] . Six microbicides have progressed to late stage clinical development, however, these products, includingNonoxynol-9, C31G (Savvy), Cellulose Sulphate (Ushercell), BufferGel, PRO2000, and Carageenan (CarraGuard), failed to demonstrate efficacy in clinical trials. . However, most recently, a successful Phase 3 clinical trial of the anti-retroviral agent tenofovir formulated as a gel product resulted in protection of women andenergized the microbicide field, suggesting that highly potent ARVs might result in highly successful microbicide products, especially when combined into co-formulated microbicide products [1] . Additionally, it has recently been reported that systemic prophylactic administration of the highly potent ARV Truvada (a combination product consisting of tenofovirand emtricitabine) to men who have sex with men (MSM) provided protection from HIV transmission[ The recent failures of the initialmicrobicides focused critical attention on continued microbicide development and the types of products that must be developed. The recent trend in the development of new microbicide candidates includes the utilization of FDA approved drugs for HIV therapy that target the early stages of the HIV life cycle including entry inhibitors and reverse transcriptase inhibitors [15, 24] . As of October 2009 there were 38 on-going and planned clinical trials for the development of microbicides and six (6) of these included ARV candidates [10] . ImQuest has licensed and has begun development of the pyrimidinedione (PYD) series of ARVs that have been shown to have potent activity against the HIV-1 reverse transcriptase and also possess a second mechanism of action targeting virus entry that extends theirrange of action to HIV-2 [5, 9] . The molecules have been evaluated in a wide variety of anti-HIV in vitro efficacy and toxicity assays and the results have defined twelve microbicide candidates [4, 5] . These 12 superior compounds have been further evaluated in more specific microbicide assays in an effort to rationally prioritize the various PYD molecules for advanced preclinical and clinical development. The data generated from these experiments and included in this manuscript indicate that the pyrimidinediones as a class have similar, if not superior, in vitro activity profiles to the ARV microbicide candidates currently being developed [17, 18, 26] .
These results, combined with the dual mechanism of action which targets virus entry and reverse transcription, makes the PYD series of molecules highly attractive candidates as topical microbicides. Our results would suggest that PYD analogs with cyclopropyl and 3-cyclopenten-1-yl substitutions at the N1 of the pyrimidinediones represent highly attractive candidates for further development as topical anti-HIV microbicides. Twelve of 68 active pyrimidinedione compounds [5] were used in these evaluations (Figure 1 The CPE assay was performed as previously described [6] . Briefly, serially diluted compound was added to a 96-well round bottom microtiter plate in triplicate. CEM-SS cells at a concentration of 2.5 x 10 3 cells per well and HIV-1 IIIB at the appropriate pre-determined titer were sequentially added to the microtiter plate. The cultures were incubated at 5% CO 2 /37°C for six days. Following the incubation, the microtiter plates were stained with XTT tetrazolium dye (Sigma, St. Louis, MO) to evaluate the efficacy and toxicity of the test compound(s). AZT was evaluated in parallel as a positive control for the assay.
Virus Entry Inhibition Assay Following the overnight incubation, test compound was serially diluted and added to the cells in triplicate in a volume of 50 L per well. HIV-1 IIIB was diluted to a pre-determined titer in assay medium and added to the microtiter plate. The cultures were incubated for 2 hours at 37°C/5% CO 2 . Following the incubation, the monolayers were washed three times with RPMI1640
(without additives) to remove residual extracellular compound and unbound virus, and incubated at 37°C/5% CO 2 for an additional 48 hours. Following the incubation, toxicity plates were evaluated by XTT staining, as previously described [6] and efficacy plates were evaluated by chemiluminescence detection using Gal-Screen (Applied Biosystems) according to the manufacturer's instructions. Chicago Sky Blue was evaluated in parallel as a positive control for the assay. The assay was performed as previously described [35] . PBMC based anti-HIV assays were performed as previously described [35] . Briefly, PHA-stimulated PBMCs cultured in the presence of IL-2 were suspended at 1 x 10 6 cells/mL and were added to a 96-well round-bottom plate. Serially diluted test materials were added to the plate in triplicate followed by the appropriate pre-titered strain of HIV. The culture was incubated for 7 days at 37°C/5% CO 2 .
Following the incubation, supernatants were collected for analysis of virus replication by supernatant RT activity and cells analyzed for viability by XTT dye reduction. AZT was used as an internal assay standard. Clinical subtypes of virus that represent HIV strains found in geographic locales where microbicide products are most likely to be clinically evaluated (clades B, C and E) were utilized. Monocyte-macrophage based anti-HIV assays were performed as previously described [35] .
Briefly, monocyte-macrophage derived from human PBMCs (4x10 6 cells/well) were plated for 5
to 7 days at 37 o C/5% CO 2 . On the day of assay, the cell monolayer was gently washed with HBSS or DPBS several times to eliminate residual PBMCs. After the final wash, 50 mL of supplemented RPMI 1640 was placed in each well and 100 µL of compound prepared at 2 times the high test concentration was transferred to the flat-bottom 96-well plate containing the cells.
A pre-determined titer of HIV-1 BaL was added to the appropriate wells in a 50 µL volume. Immediately following the infection period, and at 24 and 48 hours post-infection, the cell monolayers were washed with RPMI1640 (without additives) to remove residual compound and virus-infected cells. The cultures were incubated for 6 days at which time antiviral activity was assessed by evaluating cell-free supernatants for virus content by reverse transcriptase (RT) assay as described previously [6] . Cytotoxicity was evaluated in parallel using XTT dye reduction. Penicillin/Streptmycin was evaluated in parallel as a positive control for the assay.
Lactobacillus Toxicity Assay
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The assay was performed as previously described [22] . Briefly, in a 15 mL conical tube 10 mL of MRS media was inoculated with a stab from a frozen glycerol stock of Lactobacillus crispatus, jenseni, or acidophilus and was incubated for 24 hours at 37C in an anaerobic chamber. The overnight culture was diluted in MRS media until an absorbance of 0.06 at 670 nm was obtained. Six serial ½ log dilutions of the compound were performed and were added in a volume of 100 L to the plate followed by the addition of 100 L of the diluted bacteria. The plates were placed in an anaerobic chamber and were incubated at 37C for 24 hours. Following the incubation the plates were read spectrophotometrically at 490 nm on a Spectramax Plus 384 spectrophotometer (Molecular Devices, Sunnyvale, CA). Statistical Software Used to Generate EC 50 and TC 50 concentrations. Table 1 and provide comprehensive efficacy data to allow the prioritization of the active pyrimidinedione microbicide candidates. Efficacy of Pyrimidinediones Against Subtype Viruses Relevant to MicrobicideDevelopment The presence of the normal hydrogen peroxide producingLactobacillus flora of the vagina is critical to a healthy vaginal environment. Each PYD was evaluated for toxicity to three strains of Lactobacilli normally found in the vagina, including Lactobacillus acidophilus, Lactobacillus jensenii and Lactobacillus crispatus. The PYDs were found to be nontoxic to these normal vaginal microorganisms at concentrations 10 4 to 10 6 times higher than those concentrations required for antiviral activity. Concentrations which inhibited the growth of the Lactobacilli ranged from 40 M to >500 M. IQP-0405 and IQP-0558 were the least toxic compounds with 50% toxicity concentrations (TC 50 's) of >500 M against all strains of Lactobacillus evaluated.
IQP-0407 and IQP-1187 were found to possess the greatest toxicity, however, their defined average TC 50 's were 66.1 M and 48.3 M, respectively, well above the antiviral activity of the molecules. The remaining compounds had only marginal toxicity with TC 50 's ranging from 101.8 M to >500 M. Thus, the PYDsare considered to have little to no toxicity to the normal vaginal flora. These toxicity data are presented in Table 2 . Table 3 .
The seven PYDs were also evaluated in assays evaluating CD4-independent and CD4-dependent virus transmission. Consistent with mechanistic data indicating that CD4 was necessary for the activity of the PYDs, all of the compounds tested were unable to inhibit the Table 4 . than the defined efficacy concentrations. Theexperimentally determined toxicity in most cases was attributable to precipitation of the compound, as opposed to overt toxicity to the cells or bacteria. Without an approved and/or highly successful microbicide product, there currently does not exist a "gold-standard" for use as a model for the development of a superior microbicide. In choosing inhibitors to prioritize for continued development, algorithms exist which assist with the definition of the microbicidal properties of the compounds in comparison with others that have progressed to human trials or are currently in development. PRO2000 has been in development since the mid-1990s and until recently was the most advanced compound in human clinical trials. PRO2000 is a HIV inhibitor that targets entry, specifically the CD4/gp120
interaction, and possesses sub-micromolar antiviral activity and was robust and potent enough in the in vitro assay systems used to advance compounds in order to move forward to human clinical trial. Unfortunately, results from a Phase III clinical trial data indicated that PRO2000
was not protective against the vaginal transmission of HIV[ (thiocarboxanilide) has progressed to advanced stages of microbicide development. UC781 possesses nanomolar concentration activity and a TI of approximately 62,000 [7] but has a yellow color and sulfur odor, which are not ideal characteristics for a microbicide. Additionally, unlike the lead pyrimidinediones, UC781 appears to bemore unstable in aqueous solutions [16] . NNRTI-resistant virus strains which preexist in the population and the relative ease of selection of highly NNRTI-resistant viruses to the compound render UC781 a problematic microbicide for use unless it was a component of a microbicide combination product. Thus, the PYDs represent a class of compounds that meet all of the advantageous in vitro characteristics of a microbicide and might be superior to each of these two NNRTIs. The PYDs are colorless molecules that have nanomolar to sub-nanomolar activity and little to no cellular toxicity, yielding TIs>100,000
and in some cases >1,000,000. The FDA approved CCR5-antagonist Maraviroc (Selzentry), exhibits activity against CCR5-tropic strains of virus in the low nanomolar concentration range.
Although possessing similarin vitro activity to the PYDs, maraviroc is only active against CCR5-tropic strains of virus. Although it is known that a large percentage of the sexually transmitted viruses have CCR5 specificity it has not been conclusively shown that CXCR4-tropic viruses are not sexually transmitted. The PYDs are highly active against CXCR4-, CCR5-and dual-tropic (CXCR4/CCR5) viruses and also possess an entry inhibitory mechanism, yielding antiviral properties that might make them equivalent or superior to maraviroc. As noted above, the combination of maraviroc and a PYD would represent an effective combination product with complementary and non-overlappingantiviral mechanisms of action. The dogma surrounding potential microbicide candidates has previously involved the compound exhibiting anti-HIV activity at sub-micromolar concentrations and having a mechanism of action that targeted the early pre-integration steps in virus replication including attachment, entry and reverse transcription [33] . That viewpoint and focus however is changing with the introduction of integrase and protease inhibitors into the microbicide pipeline [11] . Not only do many of the compounds in development specifically target virus replication as traditional anti-retroviral agents (ARVs) but some of the compounds now in development are already approved for use as therapeutic agents [10, 15, 24] . The data presented herein summarizes the initial in vitro efficacy and toxicity evaluations needed to define and prioritize the PYDcongeners for continued microbicide development. Although the activity of the compounds is relatively similar, there are sevencompounds from this subset of highly active pyrimidinedione analogs that we believe have properties that provide a rationale for the performance of additional evaluations as a means to define the optimal lead candidate. These highly active and potent In each individual assay, mean toxicity values are derived from a minimum of three replicate wells. 
